US OptionsDetailed Quotes
AZN241227C67000
- 0.01
- -0.12-92.31%
15min DelayClose Dec 27 16:00 ET
0.05High0.01Low
0.05Open0.13Pre Close20 Volume6.97K Open Interest67.00Strike Price46.00Turnover1342.97%IV1.13%PremiumDec 27, 2024Expiry Date0.00Intrinsic Value100Multiplier0DDays to Expiry0.01Extrinsic Value100Contract SizeAmericanOptions Type0.0530Delta0.2411Gamma6626.00Leverage Ratio-250.2872Theta0.0000Rho351.40Eff Leverage0.0000Vega
AstraZeneca Stock Discussion
Sign in to post a comment
🔔 This Week’s PDUFA:
$Ionis Pharmaceuticals (IONS.US)$ : 🤔
⇨ IONIS-APOCIII-LRx (Olezarsen)
‣ FCS (Familial chylomicronemia syndrome)
‣ PDUFA: 12/19/24 (NDA)
🗓️ Last Week’s PDUFA Decisions:
$Checkpoint Therapeutics (CKPT.US)$ : Approved 12/13/24 ✅
⇨ UNLOXCYT (cosibelimab-ipdl)
‣ metastatic or locally advanced cSCC (cutaneous squamous cell carcinoma)
‣ PDUFA: 12/28/24 (resubmitted BLA)
$Neurocrine Biosciences (NBIX.US)$ : Approved 12/13/24 ✅
⇨ CRENESSITY™ (crin...
$Ionis Pharmaceuticals (IONS.US)$ : 🤔
⇨ IONIS-APOCIII-LRx (Olezarsen)
‣ FCS (Familial chylomicronemia syndrome)
‣ PDUFA: 12/19/24 (NDA)
🗓️ Last Week’s PDUFA Decisions:
$Checkpoint Therapeutics (CKPT.US)$ : Approved 12/13/24 ✅
⇨ UNLOXCYT (cosibelimab-ipdl)
‣ metastatic or locally advanced cSCC (cutaneous squamous cell carcinoma)
‣ PDUFA: 12/28/24 (resubmitted BLA)
$Neurocrine Biosciences (NBIX.US)$ : Approved 12/13/24 ✅
⇨ CRENESSITY™ (crin...
3
3
$Esperion Therapeutics (ESPR.US)$ Acquiring Esperion Therapeutics could be a strategic move for a big pharmaceutical company for several compelling reasons. Here are the main factors that suggest an acquisition could be beneficial for a larger player in the pharmaceutical industry:
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...
10
2
4
$Esperion Therapeutics (ESPR.US)$ $Esperion Therapeutics (ESPR.US)$ Esperion Therapeutics (ESPR) is a biotech company that focuses on developing and commercializing therapies to lower cholesterol, specifically offering the only FDA-approved statin alternatives: NEXLIZET and NEXLETOL for PRIMARY PREVENTION. These drugs are designed for individuals who are statin intolerant or cannot achieve adequate cholesterol lowering with statin...
+4
6
9
1
A quick update of my trading activities in this week (9 to 13 Dec 2024).
New Positions
$Symbotic (SYM.US)$ , $IonQ Inc (IONQ.US)$ , $Alphabet-A (GOOGL.US)$ , $PepsiCo (PEP.US)$ , $Futu Holdings Ltd (FUTU.US)$
Sold out Positions
$Hershey (HSY.US)$ , $UnitedHealth (UNH.US)$ , $Taiwan Semiconductor (TSM.US)$
Increased / Decreased Positions
None
Remarks
- I sold out $Hershey (HSY.US)$ after buyout news came out. I took decent profit from this rumour.
- Just few days after I bought $UnitedHealth (UNH.US)$ , I sold ...
New Positions
$Symbotic (SYM.US)$ , $IonQ Inc (IONQ.US)$ , $Alphabet-A (GOOGL.US)$ , $PepsiCo (PEP.US)$ , $Futu Holdings Ltd (FUTU.US)$
Sold out Positions
$Hershey (HSY.US)$ , $UnitedHealth (UNH.US)$ , $Taiwan Semiconductor (TSM.US)$
Increased / Decreased Positions
None
Remarks
- I sold out $Hershey (HSY.US)$ after buyout news came out. I took decent profit from this rumour.
- Just few days after I bought $UnitedHealth (UNH.US)$ , I sold ...
loading...
8
Buckle up! See FDA PDUFA update 👇
$Ionis Pharmaceuticals (IONS.US)$ ⇨ IONIS-APOCIII-LRx (Olezarsen)
$ZLDPF ⇨ Glepaglutide
$Rhythm Pharmaceuticals (RYTM.US)$ ⇨ IMCIVREE™ (Setmelanotide)
$Mirum Pharmaceuticals (MIRM.US)$ ⇨ Chenodal® (chenodiol)
$Checkpoint Therapeutics (CKPT.US)$ ⇨ Cosibelimab (CK-301)
$Neurocrine Biosciences (NBIX.US)$ ⇨ Crinecerfont capsule
$Bristol-Myers Squibb (BMY.US)$ ⇨ Opdivo® Subcutaneous (nivolumab + hyaluronidase)
$Neurocrine Biosciences (NBIX.US)$ ⇨ Crinecerfont oral solution
$BeiGene (BGNE.US)$ ⇨ Tisleli...
$Ionis Pharmaceuticals (IONS.US)$ ⇨ IONIS-APOCIII-LRx (Olezarsen)
$ZLDPF ⇨ Glepaglutide
$Rhythm Pharmaceuticals (RYTM.US)$ ⇨ IMCIVREE™ (Setmelanotide)
$Mirum Pharmaceuticals (MIRM.US)$ ⇨ Chenodal® (chenodiol)
$Checkpoint Therapeutics (CKPT.US)$ ⇨ Cosibelimab (CK-301)
$Neurocrine Biosciences (NBIX.US)$ ⇨ Crinecerfont capsule
$Bristol-Myers Squibb (BMY.US)$ ⇨ Opdivo® Subcutaneous (nivolumab + hyaluronidase)
$Neurocrine Biosciences (NBIX.US)$ ⇨ Crinecerfont oral solution
$BeiGene (BGNE.US)$ ⇨ Tisleli...
6
1
Buckle up! See FDA PDUFA update 👇🧵
$Ionis Pharmaceuticals (IONS.US)$ ⇨ IONIS-APOCIII-LRx (Olezarsen)
$ZLDPF ⇨ Glepaglutide
$Rhythm Pharmaceuticals (RYTM.US)$ ⇨ IMCIVREE™ (Setmelanotide)
$Mirum Pharmaceuticals (MIRM.US)$ ⇨ Chenodal® (chenodiol)
$Checkpoint Therapeutics (CKPT.US)$ ⇨ Cosibelimab (CK-301)
$Neurocrine Biosciences (NBIX.US)$ ⇨ Crinecerfont capsule
$Bristol-Myers Squibb (BMY.US)$ ⇨ Opdivo® Subcutaneous (nivolumab + hyaluronidase)
$Neurocrine Biosciences (NBIX.US)$ ⇨ Crinece...
$Ionis Pharmaceuticals (IONS.US)$ ⇨ IONIS-APOCIII-LRx (Olezarsen)
$ZLDPF ⇨ Glepaglutide
$Rhythm Pharmaceuticals (RYTM.US)$ ⇨ IMCIVREE™ (Setmelanotide)
$Mirum Pharmaceuticals (MIRM.US)$ ⇨ Chenodal® (chenodiol)
$Checkpoint Therapeutics (CKPT.US)$ ⇨ Cosibelimab (CK-301)
$Neurocrine Biosciences (NBIX.US)$ ⇨ Crinecerfont capsule
$Bristol-Myers Squibb (BMY.US)$ ⇨ Opdivo® Subcutaneous (nivolumab + hyaluronidase)
$Neurocrine Biosciences (NBIX.US)$ ⇨ Crinece...
4
See FDA PDUFA update 👇
$Applied Therapeutics (APLT.US)$ : 🤔
⇨ Govorestat
‣ Classic Galactosemia
‣ PDUFA: 11/28/24 (NDA)
🗓️ Last Week’s Adcom & PDUFA decisions:
$BridgeBio Pharma (BBIO.US)$ : Approved 11/22 ✅
⇨Attruby (Acoramidis)
‣ ATTR-CM (transthyretin amyloid cardiomyopathy)
‣ PDUFA: 11/29/24 (NDA)
$AstraZeneca (AZN.US)$ : Discussion, no vote
⇨ Andexxa (coagulation factor Xa)
‣ Life-threatening or uncontrolled bleeding
‣ Adcom: 11/21/24 (sBLA)
$Jazz Pharmaceuticals (JAZZ.US)$ & $Zymeworks (ZYME.US)$ : Approve...
$Applied Therapeutics (APLT.US)$ : 🤔
⇨ Govorestat
‣ Classic Galactosemia
‣ PDUFA: 11/28/24 (NDA)
🗓️ Last Week’s Adcom & PDUFA decisions:
$BridgeBio Pharma (BBIO.US)$ : Approved 11/22 ✅
⇨Attruby (Acoramidis)
‣ ATTR-CM (transthyretin amyloid cardiomyopathy)
‣ PDUFA: 11/29/24 (NDA)
$AstraZeneca (AZN.US)$ : Discussion, no vote
⇨ Andexxa (coagulation factor Xa)
‣ Life-threatening or uncontrolled bleeding
‣ Adcom: 11/21/24 (sBLA)
$Jazz Pharmaceuticals (JAZZ.US)$ & $Zymeworks (ZYME.US)$ : Approve...
7
1
A quick update of my trading activities in this week (18 to 22 Nov).
New Positions
$Taiwan Semiconductor (TSM.US)$ , $Broadcom (AVGO.US)$ , $Johnson & Johnson (JNJ.US)$ , $Pfizer (PFE.US)$ , $Coca-Cola (KO.US)$ , $Occidental Petroleum (OXY.US)$
Sold out Positions
$Disney (DIS.US)$
Increased Positions
$Novo-Nordisk A/S (NVO.US)$ , $AstraZeneca (AZN.US)$ , $Huntington Ingalls Industries (HII.US)$
Decreased Positions
None
New Positions
$Taiwan Semiconductor (TSM.US)$ , $Broadcom (AVGO.US)$ , $Johnson & Johnson (JNJ.US)$ , $Pfizer (PFE.US)$ , $Coca-Cola (KO.US)$ , $Occidental Petroleum (OXY.US)$
Sold out Positions
$Disney (DIS.US)$
Increased Positions
$Novo-Nordisk A/S (NVO.US)$ , $AstraZeneca (AZN.US)$ , $Huntington Ingalls Industries (HII.US)$
Decreased Positions
None
+1
loading...
10
1
Morning Movers
Gapping up
$Comcast (CMCSA.US)$ stock increased by 2.5% following a report by the WSJ that the media giant was nearing approval for a $7 billion spinoff of its cable TV assets.
$NVIDIA (NVDA.US)$ stock went up by 0.44%, building on the near 5% gains from the previous session as the market anticipates its upcoming quarterly earnings report.
$Keysight Technologies (KEYS.US)$ stock jumped 9.4% after the company rel...
Gapping up
$Comcast (CMCSA.US)$ stock increased by 2.5% following a report by the WSJ that the media giant was nearing approval for a $7 billion spinoff of its cable TV assets.
$NVIDIA (NVDA.US)$ stock went up by 0.44%, building on the near 5% gains from the previous session as the market anticipates its upcoming quarterly earnings report.
$Keysight Technologies (KEYS.US)$ stock jumped 9.4% after the company rel...
18
6
7
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
No comment yet
Just Care Bears : I thought there’s a FDA approval going on on this today no news yet
Claudius NJIE Just Care Bears : yes good news is coming.
Claudius NJIE : pls run to at least 50